Evaluation the relationship between the antibodies of Helicobacter pylori and Interleukin-6 in patients with gastritis in Kirkuk province
Article Sidebar
Main Article Content
Abstract
Background:: Helicobacter pylori is recognized as the most common cause of chronіc gastrіtis, and also an important pathogenic factor in peptic ulcer disease, after colonization and persistant in the mucus layers of the human stomach causes a raised level of pro-inflammatory cytokine such as IL-6.
Materials and Methods: The study was conducted in Kirkuk city from 15th of December 2016 to 15th of June 2017 in Azady teaching hospital in Kirkuk governorate, anti H. pylori IgG level and IL-6 level were estimated by using anti H. pylori IgG ELISA kit and IL-6 ELISA kit.
Results: A total of 90 patients the interleukin-6 level and anti H. pylori IgG level in a group of untreated patients against H. pylori infection (225.592 ng/L, 1.338 pg/ml respectively) and in a group of patients who had previously treated against H. pylori infection (102.60 ng/L, 0.350 pg/ml respectively) were significantly higher as compared to those of the control group (55.91 ng/L, 0.250 pg/ml respectively).
Conclusion: There were a positive correlation between specific anti H. pylori IgG level and IL-6 level in H. pylori associated with gastric ulcer diseases.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Tikrit Journal of Pure Science is licensed under the Creative Commons Attribution 4.0 International License, which allows users to copy, create extracts, abstracts, and new works from the article, alter and revise the article, and make commercial use of the article (including reuse and/or resale of the article by commercial entities), provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made, and the licensor is not represented as endorsing the use made of the work. The authors hold the copyright for their published work on the Tikrit J. Pure Sci. website, while Tikrit J. Pure Sci. is responsible for appreciate citation of their work, which is released under CC-BY-4.0, enabling the unrestricted use, distribution, and reproduction of an article in any medium, provided that the original work is properly cited.
References
1. Shawna, L. 2007. Helicobacter pylori. Info-base Publishing .
2. Sugimoto, M.; Yamaoka, Y. and Furuta, T. 2010. Influence of interleukin polymorphisms on development of gastric cancer and peptic ulcer. World journal of gastroenterology: WJG. 16(10): 1188.
3. Robinson, K.; Argent, R.H. and Atherton, J.C. 2007. The inflammatory and immune response to Helicobacter pylori infection. Best practice & research Clinical gastroenterology21(2): pp.237-259.
4. Kang, J.M.; Kim, N.; Lee, D.H.; Park, J.H.; Lee, M.K.; Kim, J.S.; Jung, H.C. and Song, I.S. 2009. The effects of genetic polymorphisms of IL-6, IL-8, and IL-10 on Helicobacter pylori-induced gastroduodenal diseases in Korea. Journal of clinical gastroenterology, 43(5):420-8.
5. Leja, M.; Wex, T. and Malfertheiner, P. 2012. Markers for gastric cancer premalignant lesions: where do we go?. Digestive diseases, 30(3):268-76.
6. Terry, C.F.; Loukaci, V. and Green, F.R. 2000. Cooperative influence of genetic polymorphisms on
interleukin 6 transcriptional regulation. Journal of Biological Chemistry, 275(24):18138-44.
7. Nakagawa, H.; Tamura, T.; Mitsuda, Y.; Goto, Y.; Kamiya, Y.; Kondo, T.; Wakai, K. and Hamajima, N. 2013. Significant association between serum interleukin-6 and Helicobacter pylori antibody levels among H. pylori-positive Japanese adults. Mediators of inflammation. Doi: 10.1155/2013/142358 .
8. Siregar, G.A.; Salim, S. and Sitepu, R.R. 2014. Comparison of IL-6, IL-8 Concentrations in H. pylori-and non-H. pylori-associated Gastritis. The Indonesian Biomedical Journal, 6(3):163-6.
9. Qu, B.; Han, X., Ren, G.; Jia, Y., Liu, Y.; Su, J.; Wang, Z.; Wang, Y.; Wang, H.; Pan, J. and Liu, L.L. 2016. Influence of H. pylori CagA coupled with alcohol consumption on cytokine profiles in men. Medicine, 95(5).
10. McNamara, D. and El-Omar, E. 2008. Helicobacter pylori infection and the pathogenesis of gastric cancer: a paradigm for host–bacterial interactions. Digestive and liver disease, 40(7), pp.504-509.
11. Sugimoto, M.; Yamaoka, Y. and Furuta, T. 2010. Influence of interleukin polymorphisms on development of gastric cancer and peptic ulcer. World journal of gastroenterology: WJG, 16(10), p.1188.
12. Gionchetti, P.; Vaira, D.; Campieri, M.; Holton, J.; Menegatti, M.; Belluzzi, A.; Bertinelli, E.; Ferretti, M.; Brignola, C.; Miglioli, M. and Barbara, L. 1994. Enhanced mucosal interleukin-6 and -8 in Helicobacter pylori-positive dyspeptic patients. American Journal of Gastroenterology, 89(6).
13. Kang, J.M.; Kim, N.; Lee, D.H.; Park, J.H.; Lee, M.K.; Kim, J.S.; Jung, H.C. and Song, I.S. 2009. The effects of genetic polymorphisms of IL-6, IL-8, and IL-10 on Helicobacter pylori-induced gastroduodenal diseases in Korea. Journal of clinical gastroenterology, 43(5), pp.420-428.
14. Xu, Y.; Wang, Q.; Liu, Y.; Cui, R. and Zhao, Y. 2016. Is Helicobacter pylori infection a critical risk factor for vascular dementia?. International Journal of Neuroscience, 126(10):899-903.
15. Peek, R.M.; Fiske, C. and Wilson, K.T. 2010. Role of innate immunity in Helicobacter pylori-induced gastric malignancy. Physiological reviews. 90(3):831-58.
16. Vijayvergiya, R. and Vadivelu, R. 2015. Role of Helicobacter pylori infection in pathogenesis of atherosclerosis. World journal of cardiology, 7(3): 134.
17. Kaebisch, R.; Mejías-Luque, R.; Prinz, C. and Gerhard, M. 2014. Helicobacter pylori cytotoxin-associated gene A impairs human dendritic cell maturation and function through IL-10–mediated activation of STAT3. The Journal of Immunology, 192(1):316-23.
18. Cadamuro, A.C.; Rossi, A.F.; Maniezzo, N.M. and Silva, A.E. 2014. Helicobacter pylori infection: host immune response, implications on gene expression and microRNAs. World Journal of Gastroenterology: WJG, 20(6):1424.
19. Leja, M.; Wex, T. and Malfertheiner, P. 2012. Markers for gastric cancer premalignant lesions: where do we go?. Digestive diseases, 30(3):268-76.
20. Kebapcilar, L.; Bilgir, O.; Cetinkaya, E.; Akyol, M.; Bilgir, F. and Bozkaya, G. 2010. The effect of Helicobacter pylori eradication on macrophage migration inhibitory factor, C-reactive protein and fetuin-a levels. Clinics, 65(8):799-802.
21. Peng, X.G.; Li, Y.Y.; Chen, H.T.; Zhou, Y.; Ma, J.G. and Yin, H,M. 2017. Evolution of correlation between Helicobacter pylori infection and autoimmune liver disease. Experimental and Therapeutic Medicine, 14(2): pp.1487-1490.
22. Rocha, A.; Souza, C.; Melo, F.F.; Clementino, N.C.; Marino, M.C.; Rocha, G.A. and Queiroz, D.M. 2015. Cytokine profile of patients with chronic immune thrombocytopenia affects platelet count recovery after Helicobacter pylori eradication. British journal of haematology, 168(3):421-8.
23. Ethel, Z.CH. 2014. Helicobacter pylori Treatment with Alternative Drugs Good and Cheap for Developing Countries Furazolidone - Based Treatment-Omeprazole, Furazolidone and Tetrcycline Open - Labled Trial in A Developing Country; Why Not? Gastroenterol Hepatol Open Access, 1(2): 00011.
24. Robinson, K.; Argent, R.H. and Atherton, J.C. 2007. The inflammatory and immune response to Helicobacter pylori infection. Best practice & research Clinical gastroenterology, 21(2), pp.237-259.